comparemela.com
Home
Live Updates
Aurinia Pharmaceuticals Inc. - LUPKYNIS Achieved Significant
Aurinia Pharmaceuticals Inc. - LUPKYNIS Achieved Significant
Aurinia Pharmaceuticals Inc. - LUPKYNIS Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
EDMONTON - Aurinia Pharmaceuticals Inc. today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, which found that LUPKYNIS with... | June 2, 2023
Related Keywords
Milan ,
Lombardia ,
Italy ,
Ohio ,
United States ,
Rockville ,
Maryland ,
Cleveland ,
Greg Keenan ,
Emily Littlejohn ,
Andrea Christopher ,
Nasdaq ,
Aurinia Pharmaceuticals Inc ,
European Congress ,
Aurinia Pharmaceuticals ,
Cleveland Clinic Main Campus ,
Immunologic Disease ,
Chief Medical Officer ,
Red Cell Aplasia ,
Drug Interactions ,
Moderate Hepatic Impairment ,
News Publishing ,
Aurinia Pharmaceuticals Inc Stock Exchange ,
News ,
Information ,
Press Release ,
Edmonton ,
Aurinia ,
Pharmaceuticals ,
Oday ,
Nnounced ,
The ,
Results ,
F ,
Spooled ,
Analysis ,
Hase ,
,
End ,
Aurora ,
Which ,
Hound ,
Hat ,
Upkynis Auph Ca05156v1022 ,